Pharmacokinetic study comparing doxorubicin concentrations after chemoembolization or intravenous administration in dogs with naturally occurring nonresectable hepatic carcinoma.
Pharmacokinetic study comparing doxorubicin concentrations after chemoembolization or intravenous administration in dogs with naturally occurring nonresectable hepatic carcinoma.
复制标题
DOI：
10.1111/jvim.16520
复制
发表时间：
2022-09
影响因子：
2.6
通讯作者：
Lamb, Kenneth
中科院分区：
文献类型：
--
作者：
Samuel, Nina;Weisse, Chick;Berent, Allyson C.;Rogatko, Cleo P.;Wittenburg, Luke;Lamb, Kenneth
化疗栓塞是不可切除肝癌（HC）患者的一种可行的治疗选择，可以降低化疗药物的全身毒性。比较同一患者化疗栓塞后或静脉给药后多柔比星的血清浓度。我们假设局部给药可能导致肿瘤化疗药物浓度增加，反映在可测量的血清药物浓度降低。假设局部分娩后不良血液学事件减少。17只客户拥有的HC不能完全切除的犬。前瞻性单组临床试验对不同程度的血流停滞（无停滞、停滞）进行药物洗脱珠经动脉化疗栓塞。随后在选定的患者中给予静脉内多柔比星（IVC）。通过血清多柔比星浓度时间曲线下面积（AUC）、最大血清多柔比星浓度（Cmax）和多柔比星最后一次高于定量限的时间（Tlast）定量全身暴露。治疗后的最低点试验结果用于评估不良血液学事件。进行了13次NO STASIS治疗、15次STASIS治疗和9次IVC治疗。当比较NO STASIS或STASIS与IVC治疗时，最大血清多柔比星浓度、AUC和Tlast显著较低。在具有最低值结果的患者中，在NO STASIS或STASIS治疗后未观察到不良血液学事件。2例患者在IVC治疗后发生不良血液学事件。药物洗脱微珠经动脉化疗栓塞术为不能完全切除的HC患者提供了一种可行的治疗选择，可能增加局部肿瘤多柔比星浓度，降低全身化疗药物暴露，减少不良血液学事件。
Chemoembolization is a viable treatment option for patients with nonresectable hepatic carcinoma (HC) and may allow delivery of chemotherapeutic drugs with decreased systemic toxicity. Compare the serum concentrations of doxorubicin after chemoembolization or IV administration in the same patient. We hypothesized that locoregional delivery may result in increased tumor chemotherapeutic drug concentrations, reflected by decreased measurable serum drug concentrations. Adverse hematological events were hypothesized to be decreased after locoregional delivery. Seventeen client‐owned dogs with incompletely resectable HC. Prospective, single‐arm clinical trial. Drug‐eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis (NO STASIS, STASIS). Intravenous doxorubicin (IVC) subsequently was administered in selected patients. Systemic exposure was quantified by area under the serum doxorubicin concentration time curve (AUC), maximum serum doxorubicin concentration (Cmax), and time doxorubicin was last above the limit of quantitation (Tlast). Nadir test results after treatments were used to evaluate adverse hematological events. Thirteen NO STASIS treatments, 15 STASIS treatments, and 9 IVC treatments were performed. Maximum serum doxorubicin concentration, AUC, and Tlast were significantly lower when comparing NO STASIS or STASIS to IVC treatments. Of the patients with nadir results available, no adverse hematological events were observed after NO STASIS or STASIS treatments. Two patients developed adverse hematological events after IVC treatment. Drug‐eluting bead transarterial chemoembolization offers a viable treatment option for patients with incompletely resectable HC with the potential for increased local tumor doxorubicin concentrations, decreased systemic chemotherapeutic exposure, and fewer adverse hematological events.
登录
查看更多内容
影响因子：
2.6
作者：
Rogatko CP;Weisse C;Schwarz T;Berent AC;Diniz MA
通讯作者：
Diniz MA
影响因子：
2.2
作者：
Agrawal R;Majeed M;Aqeel SB;Wang Y;Haque Z;Omar YA;Upadhyay SB;Gast T;Attar BM;Gandhi S
通讯作者：
Gandhi S
影响因子：
2.4
作者：
PATNAIK, AK;HURVITZ, AI;LIEBERMAN, PH
通讯作者：
LIEBERMAN, PH
DOI：
10.1016/j.cvsm.2016.11.016
发表时间：
2017-05-01
影响因子：
1.9
作者：
Selmic, Laura E.
通讯作者：
Selmic, Laura E.
DOI：
10.2460/javma.2002.221.1430
发表时间：
2002-11-15
期刊：
JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
影响因子：
--
作者：
Weisse, C;Clifford, CA;Solomon, JA
通讯作者：
Solomon, JA